WebApr 11, 2024 · About Muscle Maker, Inc. In late 2024, MMI began its evolution from a consumer-focused, U.S. restaurant business into a global, food-focused organization with two distinct business units: Web20 hours ago · MemryX Inc. of Ann Arbor, a startup focused on accelerating artificial intelligence (AI) processing for edge devices (any piece of hardware that controls data flow at the boundary between two networks), announced it has formed a partnership with Nota.ai, an independent AI software vendor, to streamline the development, testing, and …
PhorMed StartEngine
WebJan 29, 2024 · PhorMed is a biopharmaceutical company leading the charge in the field of genomic medicine. We are working to utilize gene therapy to treat diseases, allowing the body to heal, and give new hope to patients suffering from diseases like AML, Hodgkin’s Lymphoma, Parkinson’s disease, and viruses. $2,429,855 raised 4,078 Investors $39M WebRP-323 is under clinical development by PhorMed and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. on the television news word whizzle
Biopharmaceutical Company for Brain Health Disorders - Sage …
WebContact Information Website www.phormed.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries … WebPhorMed 185 followers on LinkedIn. Utilizing Gene Repair to Treat Diseases PhorMed is a biopharmaceutical company leading the charge in the field of genomic medicine. We are working to utilize gene therapy to treat diseases, allowing the body to heal, and give new hope to patients suffering from diseases like AML, Hodgkin’s Lymphoma, Parkinson’s … ios carthage